NewAmsterdam Pharma (NAMS) Payables (2021 - 2026)

NewAmsterdam Pharma has reported Payables for 6 years, with the latest figure at $58.3 million in Q1 2026.

• Quarterly Payables rose 96.96% year-over-year to $58.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.3 million (up 96.96% YoY) and the FY2025 annual result came in at $66.2 million, up 56.76% from the prior year.
• Payables declined to $58.3 million in Q1 2026 per NAMS's latest filing, from $66.2 million in the prior quarter.
• Over five years, Payables peaked at $66.2 million in Q4 2025 and troughed at $18.9 million in Q4 2022.
• A 5-year average of $37.3 million and a median of $30.4 million in 2023 frame the typical range for Payables.
• The sharpest annual moves came in 2025 and 2026: Payables declined 28.82% in 2025, then soared 96.96% in 2026.
• Over 5 years, Payables stood at $18.9 million in 2022, then soared by 56.22% to $29.5 million in 2023, then soared by 43.26% to $42.3 million in 2024, then soared by 56.76% to $66.2 million in 2025, then fell by 11.96% to $58.3 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $58.3 million, $66.2 million, and $48.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.